Case study

Evaluating the management and funding landscape for Duchenne Muscular Dystrophy (DMD) in Algeria, Tunisia and Morocco

Client Situation

Our client is a leading provider of pharmaceutical products for ultra-rare disorders. Their objective was to understand the treatment landscape, competitive pharmacotherapies in use, public and third-party funding opportunities, and pricing rules for ultra-rare neuromuscular disorders for the markets in scope

flag_image

Project Scope

    To evaluate the diagnostic, treatment, public funding landscape, pricing and cross border referrals for Duchenne Muscular Dystrophy (DMD)

Focus Markets

flag_image

Solutions

    We conducted extensive primary and secondary research to get detailed insights on:

  • Diagnostic and treatment landscape for ultra-rare neuromuscular diseases
  • Strengths and weaknesses of therapies available for DMD management
  • Availability and sources of public funding for ultra-orphan medications
  • Official price-setting process, impact of IRP pricing and value assessment process for ultra-orphan drugs
  • Procedure of cross border treatment and referrals
flag_image

Results

  • Successfully facilitated client understanding of the diagnostic and treatment landscape for ultra-rare neuromuscular disorders
  • Identified the funding potential for DMD drugs through public and third party routes
  • Enabled the client to gain insights on pricing and formulary inclusion process for DMD treatments
  • Enabled the client to understand treatment referral patterns for ultra-rare diseases